- Molecular NameAtenolol
- SynonymNA
- Weight266.341
- Drugbank_IDDB00335
- ACS_NO29122-68-7
- Show 2D model
- LogP (experiment)0.23
- LogP (predicted, AB/LogP v2.0)0.09
- pka9.6
- LogD (pH=7, predicted)-2.31
- Solubility (experiment)13.5 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)0.57
- LogSw (predicted, AB/LogsW2.0)27.07
- Sw (mg/ml) (predicted, ACD/Labs)14.04
- No.of HBond Donors4
- No.of HBond Acceptors5
- No.of Rotatable Bonds8
- TPSA84.58
- StatusFDA approved
- AdministrationOral or IV
- PharmacologyA selective β1 receptor antagonist, a drug belonging to the group of beta blockers (sometimes written β-blockers), a class of drugs used primarily in cardiovascular diseases.
- Absorption_value50.0
- Absorption (description)Rapidly but incompletely absorbed after oral administration.
- Caco_2-6.44
- Bioavailability58.0
- Protein binding5.0
- Volume of distribution (VD)1.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic <10%
- Half life6.1 h
- ExcretionIt is excreted almost entirely as unchanged drug, 35 to 50% of an oral dose being excreted in the urine and 30 to 50% in the faeces in 24 h; small amounts of 2-hydroxyatenolol and atenolol glucuronide are excreted in the urine.
- Urinary Excretion94
- Clerance2.4 ml/min/kg.
- ToxicityLD50=2000-3000 mg/kg(orally in mice). Symptoms of an atenolol overdose include a slow heart beat, shortness of breath, fainting, dizziness, weakness, confusion, nausea, and vomiting.
- LD50 (rat)N/A
- LD50 (mouse)N/A